Recent research has found that Americans living with HIV now have a similar life expectancy to those who do not have the virus.
Xencor has dosed the first subject in a Phase I clinical study of an engineered Interleukin-2 (IL-2) Fc cytokine, XmAb564, for the treatment of patients with autoimmune diseases.
With dozens of new Covid-19 vaccines in various stages of development, Clinical Trials Arena tracks the race to approval between those closest to the finish line.
Akston Biosciences has dosed the first participant to receive its vaccine candidate, AKS-452, in a Phase I/II trial in the Netherlands.
Swiss biotechnology company Anokion has begun patient dosing in its Phase I clinical trial of antigen-specific drug candidate ANK-700 for treating individuals with relapsing remitting multiple sclerosis (RRMS).